Ovarian metastasis from thyroid carcinoma: a case report and literature review

Giacomo Corrado1*, Giulia Pomati2, Andrea Russo3, Paolo Visca3, Cristina Vincenzoni4, Lodovico Patrizi2 and Enrico Vizza4

Abstract

Background: Papillary thyroid carcinoma is rarely associated with metastatic disease. The most common sites of metastasis are the lungs and bones, while only few cases of ovarian metastasis are described in literature.

Case: We report the case of a 51 years old woman, treated 9 years before for papillary thyroid carcinoma, presenting to our Institute with a pelvic ovarian mass revealed by ultrasound imaging. After bilateral salpingo-oophorectomy, the histologic examination detected a left ovarian metastasis from papillary thyroid carcinoma.

Conclusion: Even if the diagnosis of ovarian metastasis from thyroid carcinoma is often controversial, it should be considered when a woman with an ovarian lesion of unknown origin, has a personal history of malignant thyroid disease.

Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_193

Keywords: Thyroid carcinoma, Ovarian metastasis, Metastatic disease

Background

Papillary thyroid carcinoma is the most common histotype of thyroid carcinoma and it is associated to a good prognosis and to a loco regional spread. The presence of distant metastasis is an important prognostic factor, although it is a rare event. Distant metastasis from papillary thyroid carcinoma often occurs decades after the primary tumor and the 70% of patients who die for papillary thyroid carcinoma are disease free after the primary treatment. Moreover, the 30 years mortality rates increase to 43% as a result of a distant recurrence [1,2]. The most common metastatic sites are lung [3] and, following, bone. Instead, rare metastatic sites are brain, parotid, breast, liver, kidney, adrenal glands, ovaries, muscle and skin [4].

Ovaries are the most common metastatic sites from both genital and extragenital primaries, mostly originating in the gastrointestinal tract, and ovarian metastasis represent about 5% to 30% of all ovarian tumors [5,6].

We report a rare case of ovarian metastasis from thyroid carcinoma after 9 years from the diagnosis.

Case presentation

In December 2013 a 51 years old woman presented to our Gynecologic Oncology Unit, for the presence of a pelvic mass originating from the left ovary, occasionally detected in the ultrasound imaging during a routine check. She was 1 gravida, 1 para, with no previous gynecological pathology in her history. She referred that in 2004, following diagnosis of thyroid carcinoma, she underwent a total thyroidectomy in another hospital. The histological examination revealed a papillary thyroid carcinoma, follicular variant, involving the left thyroid lobe. She received a radio-iodine metabolic adjuvant treatment by administration of 120 mCi 131I.

No evidence of disease was detected during follow up until December 2013 when an ovarian mass was revealed by ultrasound imaging and at the magnetic resonance it measured 76 x 46 x 62 mm (Figure 1). Normal value resulted for Ca125 and HE4 (respectively 23.9 UI/ML and 100 pmol/L), while thyroglobulin was detectable (0.2 ng/ml). She underwent laparoscopic bilateral salpingo-
Figure 1 Pelvic magnetic resonance. A) Axial fat suppressed T1-weighted image after intravenous gadolinium enhancement. B) Sagittal T2-weighted image showing left solid ovarian mass.

Figure 2 Microscopic examination and immunohistochemical stains. A) The ovarian parenchyma is occupied by a thyroid type neoplasm. Note the follicles (HE 40x). B) Massive extension of the neoplasm in the parenchyma. There is no evidence of benign struma ovary or others components of teratoma (HE 40x). C) Follicular and papillary components of neoplasm (HE 100x). D) Papillary component of neoplasm. Papillae are lined by cells with ground glass nuclei. There are also some mitoses (HE 400x). E) Positive reaction of thyroglobulin antibody (HE 400x). F) Nuclear positive reaction of TTF-1 antibody (HE 100x).
oophorectomy. The histological exam showed a papillary thyroid carcinoma involving left ovary. The ovarian tumor measured $10 \times 5 \times 6$ cm and weighed 700 g. The section surface was solid and brown. We have performed one sample per centimeter of maximum dimension. Microscopic examination showed that ovarian parenchyma was nearly entirely occupied by thyroid-type neoplasm (Figure 2A-B) characterized by round follicles, of any size, and papillae (Figure 2C). Many follicles were lined by cuboidal, epithelial cells with moderate amounts of cytoplasm and round to oval and ground glass nuclei that exhibited frequent mitotic figures (Figure 2D). These cells were also positive to TTF-1 and Thyroglobulin antibodies (Figure 2E-F). Moreover, Keratin-19 (CK-19) e HBME-1 were positive while Galectin-3 (GAL-3) was negative (Figure 3A-B-C).

This neoplasm was suggestive for a metastasis because there was no evidence of benign struma ovary and the others teratomatous component.

Unfortunately, in March 2014 the CT/PET detected a left pelvic lymph nodes recurrence (SUV 10.8) and a paramedian nodular mass in proximity of the uterus (SUV 10.6). A laparoscopic evaluation showed left pelvic peritoneal carcinomatosis and a large left pelvic adenopathy (Figure 4). A left pelvic lymphadenectomy and a left pelvic peritonectomy were performed. Definitive histological examination showed a metastasis from papillary thyroid carcinoma. Actually, the patient is undergoing biological treatment with multikinase inhibitors.

**Conclusions**

Papillary thyroid carcinoma is associated with a good prognosis and with a low metastatic power. A distant metastasis from papillary thyroid carcinoma is a rare event, above all when the recurrence occurs in less common sites. For this reason, rare metastasis is often not considered during the clinical setting.

When an ovarian mass is found to contain cells with features of thyroid carcinoma, a differential diagnoses should have to be considered between thyroid cancer arising from a struma ovarii and ovarian metastasis originating from a primary thyroid carcinoma, since the prognosis and clinical management are different. Thyroid carcinoma originating from a struma ovarii, presenting a papillary histotype in 70% of all cases, is reported to occur much more commonly than an ovarian metastasis from the thyroid. As a matter of fact, struma ovarii are the 5% of ovarian teratomas, 5–10% results in malignant teratomas and metastatic diseases doesn’t reach the 23% of cases. However, when no teratomatous elements and no normal thyroid epithelial tissue are detected in the ovarian lesion, the diagnosis of metastasis with a thyroid origin is suggestive [7]. In our patient, the ovarian parenchyma was completely occupied by thyroid-type neoplasm, there was no evidence of benign struma ovary or others teratomatous component and cells were positive to TTF-1 and Thyroglobulin antibodies.

A review of literature from 1929 to 2013 can confirm the rarity of the ovarian metastasis from thyroid carcinoma. As it is shown in Table 1, only four case reports of ovarian metastasis from thyroid are described in a comprehensive manner [8-11]. The table shows that most of
patients affected by thyroid carcinoma were between the fourth and fifth decades of life at the moment of the first diagnosis and underwent $^{131}$I therapy after primary surgery. Moreover, ovarian metastasis seems to appear more commonly unilaterally. It can be inferred from the description of these cases that well differentiated thyroid carcinomas can give metastasis many years after the primary tumor. As a matter of fact, in Brogioni S et al. [10] case report, the ovarian metastasis occurred almost 5 years after the first pulmonary metastasis and 7 years after the first diagnosis. Also in Pirvu A et al. [11] report, the pulmonary metastasis occurred shortly after the thyroidectomy, while ovarian metastasis 11 years after the first diagnosis of thyroid carcinoma. Furthermore, in the well differentiated thyroid cancer group, papillary histotype seems to give ovarian metastasis more frequently than follicular. In our case ovaries had been the first metastatic site, while in three of the mentioned reports [8,10,11], the ovarian metastasis was associated with a metastatic spread, probably pointing to a biologically more aggressive disease and to a worse prognosis associated to the ovarian involvement. Further 10 cases [12-18] of ovarian spread from thyroid carcinoma are mentioned in literature but, unfortunately, no more details were provided. Besic et al. [12] in his autopsic series reported one case of ovarian metastasis from anaplastic thyroid carcinoma, while Silvesberg et al. [13], always in autopsic series, reported two cases of ovarian metastasis from anaplastic thyroid carcinoma and one from medullary thyroid carcinoma. Others two cases of ovarian metastasis from medullary thyroid carcinoma are only mentioned by Ibanez et al. [14] and Gordon et al. [15]. In another article [17] the ovarian involvement was bilateral. However, in literature there are not enough studies

![Image](https://example.com/image1.jpg)

**Figure 4** Laparoscopic and CT/PET characterization of the pelvic recurrence. A) Laparoscopic image of left pelvic peritoneal carcinomatosis. B) The large left pelvic lymphadenopathy. C) CT/PET image of a nodular mass near the uterus (SUV 10.6). D) Left pelvic lymph nodes (SUV 10.8).

---

### Table 1 Literature review of ovarian metastasis from thyroid carcinoma

| Author          | Year | N° | Age | Primary treatment                      | Histotype | $^{131}$I therapy | DFS (months) | Site of metastasis | Surgery of metastasis | $^{131}$I therapy | Status (months) |
|-----------------|------|----|-----|----------------------------------------|-----------|-------------------|--------------|---------------------|-----------------------|-------------------|-----------------|
| Young RH [8]    | 1994 | 1  | 17  | Partial thyroidectomy                  | Follicular| -                 | 144          | Brain, ovaries      | Right cystectomy       | -                 | DOD, 150         |
| Logani S [9]    | 2001 | 1  | 34  | Total thyroidectomy with lymphadenectomy| Papillary | Yes               | 132          | Ovaries             | Left oophorectomy      | Yes               | NED, 140         |
| Brogioni S [10] | 2007 | 1  | 38  | Total thyroidectomy with lymphadenectomy| Papillary | Yes               | 24           | Thymus, lungs, ovaries, brain| Bilateral oophorectomy | Yes               | DOD, 92         |
| Pirvu A [11]    | 2013 | 1  | 26  | Total thyroidectomy with lymphadenectomy| Papillary | Yes               | -            | Lungs, ovaries      | Left ovariectomy        | Yes               | AWD, 158         |
| Our experience  | 2014 | 1  | 42  | Total thyroidectomy                    | Papillary | Yes               | 108          | Ovaries             | Laparoscopic bilateral oophorectomy | No                | AWD, 111         |

NED = no evidence of disease. DOD = death of disease. AWD = alive with disease.
to draw conclusions about prognosis and best clinical management of ovarian metastasis from thyroid cancer. 131I scan and serum thyroglobulin are widely employed during the follow up of thyroid cancer and in the assessment of the best therapy to use after surgery, while immunohistochemical stain for thyroglobulin and TTF-1 is often essential in pathologic diagnosis as it has been in our experience. Moreover, Keratin-19 (CK-19) e HBME-1 were positive while Galectin-3 (GAL-3) was negative. This was due to because GAL-3 is a useful marker for diagnosis of low grade thyroid carcinomas [19] while in our case the carcinoma was an high grade.

In conclusion, the ovarian involvement by a primary thyroid cancer is a rare event, but it should be considered, since it seems to be a negative prognostic factor worsening the oncological outcome. The histopathologic evaluation, including immunohistochemical stain and the investigation of patient's history are crucial steps in the diagnosis and clinical management of ovarian metastasis from thyroid cancer.

Consent
Written informed consent was obtained by patient for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no conflict of interest.

Authors' contributions
All the authors contributed to the acquisition of data, revised the paper and gave final approval.

Author details
1Department of Oncological Surgery, Gynecologic Oncology Unit, “Regina Elena” National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
2Surgery Department, Gynecology Section and Obstetrics, Tor Vergata University, Rome, Italy. 3Pathology Department, “Regina Elena” National Cancer Institute, Rome, Italy. 4Surgery Department, Gynecologic Oncology Unit, “Regina Elena” National Cancer Institute, Rome, Italy.

Received: 29 July 2014 Accepted: 23 September 2014
Published online: 30 October 2014

References
1. Mazzaferri EL, Massoli N: Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002, 9:227–247.
2. Saleh HA, Jin B, Barnwell J, Alabashi O: Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 2010, 5:9.
3. Xue L, Luan Z, Liu Y, Zou S, Jiang J, Wu N, Lu N, Lin D: Pulmonary metastasis of a papillary thyroid carcinoma and primary lung adenocarcinoma: two coincident carcinomas at the same location. Diagn Pathol 2013, 8:26.
4. Song HJ, Xue YL, Xu YH, Qiu ZL, Luo QY: Rare metastases of differentiated thyroid carcinoma: pictorial review. Endocr Relat Cancer 2011, 18(5):165–174.
5. Ozer H, Yenicesu C, Arici S, Cetin M, Tuncer E, Cetin A: Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol 2012, 7:124.
6. Mazur MT, Hsueh S, Gersell DJ: Metastases to the female genital tract: analysis of 325 cases. Cancer 1984, 53(9):1978–1984.
7. Leite I, Cunha TM, Figueiredo JP, Felix A: Papillary carcinoma arising in struma ovarii versus ovarian metastasis from primary thyroid carcinoma: a case report and review of the literature. J Obstet Gynaecol Res 2013, 7(10):24–33.
8. Young RH, Jackson A, Wells M: Ovarian metastasis from thyroid carcinoma 12 years after partial thyroidectomy mimicking struma ovarii: report of a case. Int J Gynecol Pathol 1994, 13(2):181–185.
9. Logani S, Baloch ZW, Snyder PJ, Weinstein R, LiVolsi VA: Cystic ovarian metastasis from papillary thyroid carcinoma: a case report. Thyroid 2001, 11(11):1073–1075.
10. Brogioni S, Vacava P, Tomisti L, Martino E, Macchia E: A special case of bilateral ovarian metastasis in a woman with papillary carcinoma of the thyroid. Exp Clin Endocrinol Diabetes 2007, 115(6):397–400.
11. Pireu A, Guigard S, Biais H, Chaffanjon P: Peroperative detection with a gamma probe of pelvic metastasis after differentiated thyroid carcinoma in female patients: about two cases and management reflections. Chirurgia (Bucur) 2013, 108(1):126–129.
12. Besic N, Gazic B: Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid 2013, 23(6):709–713.
13. Silverberg SG, Hutter RV, Foote FW Jr: Fatal carcinoma of the thyroid: histology, metastases, and causes of death. Cancer 1970, 25(4):792–802.
14. Ibanez ML, Cole WW, Russell WD, Clark RL: Solid carcinoma of the thyroid gland: analysis of 53 cases. Cancer 1967, 20:706–723.
15. Gordon PR, Huvos AG, Strong EW: Medullary carcinoma of the thyroid gland: a clinicopathologic study of 40 cases. Cancer 1973, 31:913–923.
16. Luis A: Metastatic ovarian tumours. In Ovarian Cancer. Edited by: Gentili F, Junqueira AC. New York: Springer-Verlag; 1968:807–814 [UICC Monograph Series].
17. Woodruff JD, Murthy YS, Bhaskar TN, Bordbar F, Tseng SS: Metastatic ovarian tumors. Am J Obstet Gynecol 1970, 107:202–209.
18. Kaufmann E: Pathology for Students and Practitioners, Volume 2. Philadelphia: P Blakiston’s Son & Co; 1929:1576–1577.
19. Bartolazzi A, Bellotti C, Sciacchitano S: Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules. Appl Immunohistochem Mol Morphol 2012, 20(1):7–27.

Cite this article as: Corrado et al.: Ovarian metastasis from thyroid carcinoma: a case report and literature review. Diagn Pathology 2014 9:193.

DOI:10.1186/s13000-014-0193-9

Submit your manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit